NextCure, Inc. (NXTC) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
NXTC currently has 3.61M outstanding shares. with moderate dilution risk from 1.55M authorized shares representing 43.1% potential dilution. The company has significantly diluted shareholders by 121.95% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 3.6M shares outstanding |
3.6M | 1.6M |
| Nov 26, 2025 |
S-3 filing: This S-3 filing relates to the resale of up to 2,523,477 shares of common stock by selling stockholders of NEXTCURE, INC. |
5.2M | 0 |
| Nov 17, 2025 |
8-K filing: NextCure, Inc. closed a private placement offering on November 14, 2025, issuing shares of common stock and pre-funded warrants, raising approximately $21.5 million in gross proceeds. ($21.5M proceeds) |
2.7M | 0 |
| Nov 05, 2025 |
10-Q filing | 2.7M shares outstanding |
2.7M | 0 |
| Aug 07, 2025 |
10-Q filing | 2.4M shares outstanding |
2.4M | 260K |
| Jul 18, 2025 |
S-3 filing: Resale of up to 338,636 shares of common stock by the selling stockholder. |
2.7M | 0 |
| Jul 14, 2025 |
Stock Split
8-K filing: Stock split 1-for-12 | Outstanding: 28,006,684 → 2,333,890 |
2.3M | 0 |
| Jun 16, 2025 |
8-K filing: NextCure, Inc. will issue and sell 4,063,633 shares of common stock to Simcere Zaiming, Inc. at a price of $0.492 per share for an aggregate purchase price of $2.0 million in a private placement. ($2.0M proceeds) |
28M | 0 |
| May 01, 2025 |
10-Q filing | 28.0M shares outstanding |
28M | 0 |
| Mar 06, 2025 |
10-K filing | 28.0M shares outstanding |
28M | 0 |
| Nov 07, 2024 |
10-Q filing | 28.0M shares outstanding |
28M | 0 |
| Aug 01, 2024 |
10-Q filing | 28.0M shares outstanding |
28M | 0 |
| May 02, 2024 |
10-Q filing | 27.9M shares outstanding |
28M | 0 |
| Mar 21, 2024 |
10-K filing | 27.8M shares outstanding |
28M | 0 |
| Nov 02, 2023 |
10-Q filing | 27.8M shares outstanding |
28M | 0 |
| Aug 04, 2023 |
S-3 filing: NextCure, Inc. files an S-3 registration statement for the potential offering of common stock, preferred stock, debt securities, warrants, and units, with a total proposed amount of $180,000,000. They also plan an at the market common stock offering through Leerink Partners for up to $16,762,573. |
28M | 0 |
| Aug 03, 2023 |
10-Q filing | 27.8M shares outstanding |
28M | 0 |
| May 04, 2023 |
10-Q filing | 27.8M shares outstanding |
28M | 0 |
| Mar 02, 2023 |
10-K filing | 27.7M shares outstanding |
28M | 0 |
| Nov 03, 2022 |
10-Q filing | 27.7M shares outstanding |
28M | 0 |
| Aug 04, 2022 |
10-Q filing | 27.7M shares outstanding |
28M | 0 |
| May 05, 2022 |
10-Q filing | 27.7M shares outstanding |
28M | 0 |
| Mar 03, 2022 |
10-K filing | 27.6M shares outstanding |
28M | 0 |
| Nov 04, 2021 |
10-Q filing | 27.6M shares outstanding |
28M | 0 |
| Aug 05, 2021 |
10-Q filing | 27.6M shares outstanding |
28M | 31K |
| May 06, 2021 |
10-Q filing | 27.5M shares outstanding |
28M | 93K |
| Mar 05, 2021 |
POS AM filing: NextCure, Inc. is filing a POS AM to offer and sell up to an aggregate of $180,000,000 of Common Stock, Preferred Stock, Debt Securities, Warrants, and/or Units from time to time in one or more offerings. |
28M | 0 |
| Mar 04, 2021 |
10-K filing | 27.6M shares outstanding |
28M | 0 |
| Nov 05, 2020 |
10-Q filing | 27.6M shares outstanding |
28M | 0 |
| Aug 06, 2020 |
10-Q filing | 27.6M shares outstanding |
28M | 0 |
| May 07, 2020 |
10-Q filing | 27.5M shares outstanding |
28M | 0 |
| Mar 12, 2020 |
10-K filing | 27.5M shares outstanding |
28M | 0 |